Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16577831 | 0.91 | KDM4E (0.60) | ALDH1A1LMNAHPGDKDM4EUSP2 | |
| SCHEMBL16577887 | 0.90 | ALDH1A1 (0.49) | ALDH1A1LMNAHPGDKDM4EUSP2 | |
| SCHEMBL16577847 | 0.90 | ALDH1A1 (0.47) | ALDH1A1LMNAHPGDKDM4EUSP2 | |
| SCHEMBL16577843 | 0.89 | ALDH1A1 (0.50) | ALDH1A1LMNAHPGDKDM4EUSP2 | |
| SCHEMBL16577842 | 0.89 | ALDH1A1 (0.50) | ALDH1A1LMNAHPGDKDM4EUSP2 | |
| SCHEMBL16577839 | 0.88 | ALDH1A1 (0.48) | ALDH1A1LMNAHPGDKDM4EUSP2 | |
| SCHEMBL16577845 | 0.86 | ALDH1A1 (0.47) | ALDH1A1LMNAHPGDKDM4EUSP2 | |
| SCHEMBL16577838 | 0.86 | ALDH1A1 (0.47) | ALDH1A1LMNAHPGDKDM4EUSP2 | |
| SCHEMBL16577850 | 0.81 | ALDH1A1 (0.42) | ALDH1A1LMNAHPGDKDM4EUSP2 | |
| SCHEMBL16577849 | 0.80 | LMNA (0.42) | ALDH1A1LMNAHPGDKDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120108640-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | AQP4, AVPR2, AQP1 | ALDH1A1 687/4885LMNA 3676/4885HPGD 241/4885 |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | ALDH1A1 889/4885LMNA 3992/4885HPGD 1373/4885 |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | ABCG2, ABCB1, TRPV1 | ALDH1A1 1389/4885LMNA 3023/4885HPGD 1760/4885 |
| US-20120108640-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | SLC1A2, SLC18A2, GRIN2C | ALDH1A1 1109/4885LMNA 3939/4885HPGD 1430/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | ALDH1A1 845/4885LMNA 3842/4885HPGD 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.